Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC

Inclusion Criteria: * Voluntary participation and written informed consent; * histologically or cytologically confirmed advanced metastatic (stage IV) non-small cell lung cancer; * Patients with negative driver genes who develop oligoprogression after receiving standard first-line therapy. The oligoprogression is defined as: 1-5 metastatic lesions, and no more than 3 organs; * Age 18-75 years old; ECOG PS: 0-1; The expected survival is more than 3 months; * At least one measurable lesion; * Patients were willing to provide adequate blood and tissue samples； * Patients had adequate hematologic, renal, and liver function; * International normalised ratio (INR) ≤1.5 and partial thromboplastin time (PTT or aPTT) ≤1.5 x ULN within 7 days prior to study treatment; * The woman patients of childbearing age who must agree to take contraceptive methods during the research; * The man patients who must agree to take contraceptive methods during the research and within another 6 months after it. Exclusion Criteria: * cytologically or histologically confirmed combination with small cell lung cancer component or sarcomatoid element; * Previously received targeted therapy for advanced NSCLC (including osimertinib, erlotinib, crizotinib, etc); * Had undergone major surgical operations or had not fully recovered from previous operations within 3 weeks before enrollment; * Known active nervous system (CNS) metastases and/or carcinomatous meningitis; * Spinal cord compression for which operation and/or radical radiotherapy has not been given, or no clinical evidence of stable disease for ≥4 weeks prior to enrollment after treatment for previously diagnosed spinal cord compression; * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; patients with stable symptoms after drainage can be enrolled; * History of idiopathic pulmonary fibrosis, organized pneumonia (e.g., obliterating bronchiolitis), drug induced pneumonia, idiopathic pneumonia or evidence of active pneumonia during chest CT scanning for screening; * Clinically uncontrolled active infection, including but not limited to acute pneumonia; * Uncontrollable major epileptic seizure or superior vena cava syndrome; * Previous or current co-occurrence of other malignancies (excluding controllable non-melanoma basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the breast or cervix, superficial bladder cancer, or other carcinoma in situ); * Known hepatic diseases of clinical significance, including active viral hepatitis, alcoholic hepatitis or other hepatitis, liver cirrhosis, fatty liver, hereditary liver disease; * Active tuberculosis (TB), receiving anti-tuberculosis therapy currently or within one year prior to screening; * Use of systemic immunosuppressive therapy for any active autoimmune disease within two years prior to Day 1 of the 1st cycle; * Vaccination of live-virus vaccine within 30 days after the start of planned treatment; Inactivated seasonal influenza vaccine was permitted; * Patients has HIV-positive; * Patients judged by the investigator to be inappropriate as a subject of this study. * History of severe allergic, quasi-allergic, or other hypersensitive reactions to chimeric or humanized antibodies or fusion proteins; * Known allergy to biological drugs produced from Chinese hamster ovary cells, or to citrate monohydrate, sodium citrate dihydrate, mannitol, polysorbate (components of the study drug); * Patients who have previously received allogeneic stem cells or parenchymal organ transplants.